Canaccord raised the firm’s price target on Insulet (PODD) to $428 from $399 and keeps a Buy rating on the shares. The firm said Insulet delivered another strong beat-and-raise in Q3, driven by OUS outperformance and record new patient starts in US T1 and US T2.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: